New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 18, 2022 - Prasco launched an authorized brand alternative (ABA) of Akorn’s Zioptan (tafluprost) ophthalmic solution.
Download PDF
Return to publications
